Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.